Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Baseline characteristics of patients and biochemical analyses before and after MIPTotal populationn = 117Male, n (%)35 (29.9)Age (year)60 ± 13BMI (kg/m2)25.5 ± 4.0Symptomatic hypercalcemia19 (16.2)Nephrolithiasis36 (30.8)Peptic ulcers3 (2.6)Pancreatitis4 (3.4)Cardiovascular disease18 (15.4)Hypertension55 (47.0)Osteoporosis27 (23.1)Fragility fracture3 (2.6)Neuropsychiatric/neurocognitive symptoms7 (6.0)Neuromuscular symptoms6 (5.1)CrCl < 60 ml/min11 (9.4)Others symptoms16 (13.7)Serum creatinine (mg/dL)1.2 ± 0.7eGFR (mL/min)89.2 ± 38.1Preoperative serum calcium (mg/dL)11.8 ± 2.125-OH vitamin D (ng/mL)53.5 ± 15.624-h urinary calcium279.1 ± 112.1Preoperatve iPTH (pg/ml)459.2 ± 602.1Intraoperative iPTH (pg/ml)59.7 ± 71.1Postoperative iPTH (pg/ml)25.3 ± 17.36 months iPTH (pg/ml)23.0 ± 9.8I postoperative day serum calcium (mg/dL)9.1 ± 0.6II postoperative day serum calcium (mg/dL)9.0 ± 0.6III postoperative day serum calcium (mg/dL)8.9 ± 0.5Follow-up time (months)60 ± 1Temporary hypoparathyroidism7 (6.0)Permanent hypoparathyroidism0 (0.0)Persistent hyperparathyroidism0 (0.0)Recurrence hyperparathyroidism0 (0.0)Disease relapse0 (0.0)Data are shown as mean ± standard deviation or number (%)Abbreviations: MIP minimally invasive parathyroidectomy, BMI body mass index, CrCl creatinine clearance, eGFR estimated glomerular filtration rate, 25-OH vitamin D 25-hydroxyvitamin D3, iPTH intact-parathyroid hormone, PTX 6 months iPTH intact-parathyroid hormone measurement 6 months later the surgery interventionAnatomical pathology findings in the overall populationTotal populationn = 117Single gland disease110 (94.0) Typical adenoma100 (85.5) Atypical parathyroid adenoma10 (8.5)MGD7 (6.0) Double typical adenoma7 (6.0) Parathyroid hyperplasia0 (0.0)Parathyroid carcinoma0 (0.0)Size of parathyroid gland (mm)a24 ± 14Weight of parathyroid gland (mg)33 ± 42Clinical/intraoperative adherence0 (0.0)Pseudocapsular Invasion4 (3.4)Bands of fibrosis9 (7.7)Pronounced trabecular growth13 (11.1)Mitotic rates of > 1/10 HPFS8 (6.8)Tumor necrosisb1 (0.9)Nuclear pleomorphism4 (3.4)Cystic degeneration10 (8.5)Thick capsule4 (3.4)Hemosiderin deposition5 (4.3)Hematic extravasion7 (6.0)Ki-67+ < 1%11 (9.4)Ki-67+ > 4%4 (3.4)Galactin-3 +29 (24.8)PGP 9.5 +17 (14.3)Criteria for malignancyc0 (0.0)Data are show as mean ± standard deviation or number (%)Abbreviations: MGD multiglandular disease, HPFS high-power fieldsaMaximum diameterbNot associated with tumorous infarction or fine-needle aspirationcInvasion of capsule, vascular, perineural, soft tissue, or surrounding structures (including thyroid, recurrent laryngeal nerve, trachea, esophagus) or documented metastatic diseaseComparison between patients diagnosed with TA (group A) and patients diagnosed with APA (group B)Group Atypical adenomaGroup Batypical adenomaP-valuen = 107n = 10Male n (%)30 (28.0)5 (50.0)0.105Age (year)60 ± 1362 ± 130.661BMI (kg/m2)25.4 ± 4.026.4 ± 3.60.258Symptomatic hypercalcemia13 (12.1)6 (60.0)0.001Nephrolithiasis34 (31.8)2 (20.0)0.722Peptic ulcers2 (1.9)1 (10.0)0.237Pancreatitis3 (2.8)2 1.9)0.304Cardiovascular disease16 (15.0)2 (20.0)0.651Hypertension53 (49.5)2 (20.0)0.101Osteoporosis24 (22.4)3 (30.0)0.695Fragility fracture1 (0.9)2 (20.0)0.019Neuropsychiatric/neurocognitive symptoms6 (5.6)1 (10.0)0.474Neuromuscular symptoms5 (4.7)1 10.0)0.422CrCl < 60 ml/min10 (9.3)1 (10.0)1.000Others symptoms14 (13.1)2 (20.0)0.625Serum creatinine (mg/dL)1.2 ± 0.71.1 ± 0.70.750eGFR (mL/min)89.2 ± 38.789.9 ± 33.30.884Preoperative serum calcium (mg/dL)11.7 ± 2.113.6 ± 1.50.00125-OH vitamin D (ng/mL)53.2 ± 15.856.8 ± 13.40.37224-h urinary calcium269.9 ± 102.8376.8 ± 160.70.036Preoperatve iPTH (pg/ml)390.1 ± 473.61198.7 ± 1168.70.002Intraoperative iPTH (pg/ml)56.6 ± 68.993.1 ± 88.90.108Postoperative iPTH (pg/ml)24.8 ± 16.831.4 ± 22.20.0996 mounths iPTH (pg/ml)23.0 ± 10.022.3 ± 6.40.696I Postoperative day serum calcium (mg/dL)9.1 ± 0.69.2 ± 0.60.488II Postoperative day serum calcium (mg/dL)9.1 ± 0.68.9 ± 0.60.111III Postoperative day serum calcium (mg/dL)8.9 ± 0.48.8 ± 0.60.747Follow-up time (mounths)60 ± 261 ± 40.551Temporary hypoparathyroidism6 (5.6)1 (10.0)0.474Permanent hypoparathyroidism0 (0.0)0 (0.0): Persistent hyperparathyroidism0 (0.0)0 (0.0): Data are shown as mean ± standard deviation or number (%)Abbreviations: TA typical adenoma, APA atypical parathyroid adenoma, BMI body mass index, CrCl creatinine clearance, eGFR estimated glomerular filtration rate, 25-OH vitamin D 25-hydroxyvitamin D3, iPTH intact-parathyroid hormone, PTX 6 months iPTH iPTH measurement 6 months later the surgery interventionAnatomical pathology findings comparison between TA (group A) and APA (group B)Group Atypical adenomaGroup Batypical adenomaP valuen = 107n = 10Single gland disease100 (93.5)10 (100.0)1.000Double typical adenoma7 (6.5)0(0.0)1.000Size of parathyroid gland (mm) a23 ± 1325 ± 300.001Weight of parathyroid gland (mg)40 ± 16120 ± 64< 0.001Clinical/intraoperative adherence0 (0.0)0 (0.0): Pseudocapsular invasion0 (0.0)4 (40.0)< 0.001Bands of fibrosis4 (3.7)5 (50.0)< 0.001Pronounced trabecular growth7 (6.5)6 (60.0)< 0.001Mitotic rates of > 1/10 HPFS2 (1.9)6 (60.0)< 0.001Tumor necrosisb0 (0.0)1 (10.0)0.085Nuclear pleomorphism2 (1.9)2 (20.0)0.036Cystic degeneration8 (7.5)2 (20.0)0.204Thick capsule0 (0.0)4 (40.0)< 0.001Hemosiderin deposition3 (2.8)2 (20.0)0.058Hematic extravasion5 (4.7)2 (20.0)0.110Ki-67+ < 1%11 (10.3)0 (0.0)0.598Ki-67+ > 4%0 (0.0)4 (40.0)< 0.001Galactin-3 +22 (20.6)7 (70.0)0.002PGP 9.5 +13 (12.1)4 (40.0)0.038Data are show as mean ± standard deviation or number (%)Abbreviations: HPFS high-power fieldsaMaximum diameterbNot associated with tumorous infarction or fine-needle aspirationa Pseudocapsular invasion: cell proliferation is closer with capsular and vascular structures in the atypical parathyroid adenoma but there is no sure invasion (hematoxylin and eosin (H&E) staining, × 40 original magnification). b Pseudocapsular invasion: immunohistochemical staining for CD31/CD34 underlining the vascular plot allows to verify if there is an invasion of tumor cells and therefore improve diagnostic quality (× 40 original magnification)Nuclear pleomorphism: characteristic dosimetry and hyperchromasia of tumor cells nuclei in high-power view section of atypical parathyroid adenoma (H&E staining, × 100 original magnification)Thick capsule: a characteristic of the atypical parathyroid adenoma is also present in parathyroid carcinoma; therefore, it requires a strict differential diagnosis (H&E, × 40 original magnification)a Ki-67+ > 4%: immunohistochemical staining for Ki-67 underlines the high mitotic rates of APA (MIB/Ki-67, × 40 original magnification). b Ki-67+ < 4%: immunohistochemical staining for Ki-67 underlines the low mitotic rates of TA (MIB/Ki-67, × 40 original magnification)a Galectin-3+: immunohistochemistry for Galectin-3 shows widespread and marked cytoplasmic and nuclear staining of APA (× 400 original magnification). b Galectin-3 +: immunohistochemistry for galectin-3 shows weakly cytoplasmic and nuclear staining of TA (× 400 original magnification)

Source: Results. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Cohort study.

Cohort study

Examines exposures and outcomes over time within a defined group.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

We performed a retrospective cohort study and enrolled 117 patients with primary hyperparathyroidism undergoing minimally invasive parathyroidectomy.

Source: Abstract.

None of the patients were affected by parathyroid carcinoma.

Source: Abstract.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Atypical parathyroid adenoma: clinical and anatomical pathologic features

Cohort study · World Journal of Surgical Oncology · 2021

Original publication title

Atypical parathyroid adenoma: clinical and anatomical pathologic features

Alessandro Galani; Riccardo Morandi; Mira Dimko; Sarah Molfino; Carla Baronchelli; Silvia Lai; Federico Gheza; Carlo Cappelli; Claudio Casella

© The Author(s) 2021

Original publication · Publisher record · CC BY 4.0 · CC0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Atypical parathyroid adenoma is a tumor that has characteristics both of typical adenoma and parathyroid carcinoma. The diagnosis is reached by excluding with strict methods the presence of malignancy criteria. Atypical parathyroid adenoma compared to typical adenoma showed significant clinical, hematochemical, histological, and immunohistochemical differences. We did not find any disease relapse in the 10 patients with atypical parathyroid adenoma during 60 months of follow-up time.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Primary hyperparathyroidism is an endocrine pathology that affects calcium metabolism. Patients with primary hyperparathyroidism have high concentrations of serum calcium or high concentrations of parathyroid hormone, or incorrect parathyroid hormone levels for serum calcium values. Primary hyperparathyroidism is due to the presence of an adenoma/single-gland disease in 80 to 85%. Multiple gland disease or hyperplasia accounts for 10 to 15% of cases of primary hyperparathyroidism. Atypical parathyroid adenoma and parathyroid carcinoma are both responsible for about 1.2 to 1.3% and 1% or less of primary hyperparathyroidism, respectively.

Source: Background

Abstract: What methods does the paper describe?

We performed a retrospective cohort study and enrolled 117 patients with primary hyperparathyroidism undergoing minimally invasive parathyroidectomy. Histological and immunohistochemical examination showed that 107 patients (91.5%) were diagnosed with typical adenoma (group A), while 10 patients (8.5%) were diagnosed with atypical parathyroid adenoma (group B). None of the patients were affected by parathyroid carcinoma.

Source: Methods

Abstract: Results

Significant statistical differences were found in histological and immunohistochemical parameters as pseudocapsular invasion (p <  0.001), bands of fibrosis (p <  0.001), pronounced trabecular growth (p <  0.001), mitotic rates of > 1/10 high-power fields (HPFs) (p <  0.001), nuclear pleomorphism (p = 0.036), thick capsule (p <  0.001), Ki-67+ > 4% (p <  0.001), galectin-3 + (p = 0.002), and protein gene product (PGP) 9.5 + (p = 0.038).

Source: Results

Abstract: Conclusions

Atypical parathyroid adenoma is a tumor that has characteristics both of typical adenoma and parathyroid carcinoma. The diagnosis is reached by excluding with strict methods the presence of malignancy criteria. Atypical parathyroid adenoma compared to typical adenoma showed significant clinical, hematochemical, histological, and immunohistochemical differences. We did not find any disease relapse in the 10 patients with atypical parathyroid adenoma during 60 months of follow-up time.

Source: Conclusions
Authors’ abstract

Background

Primary hyperparathyroidism is an endocrine pathology that affects calcium metabolism. Patients with primary hyperparathyroidism have high concentrations of serum calcium or high concentrations of parathyroid hormone, or incorrect parathyroid hormone levels for serum calcium values. Primary hyperparathyroidism is due to the presence of an adenoma/single-gland disease in 80 to 85%. Multiple gland disease or hyperplasia accounts for 10 to 15% of cases of primary hyperparathyroidism. Atypical parathyroid adenoma and parathyroid carcinoma are both responsible for about 1.2 to 1.3% and 1% or less of primary hyperparathyroidism, respectively.

Methods

We performed a retrospective cohort study and enrolled 117 patients with primary hyperparathyroidism undergoing minimally invasive parathyroidectomy. Histological and immunohistochemical examination showed that 107 patients (91.5%) were diagnosed with typical adenoma (group A), while 10 patients (8.5%) were diagnosed with atypical parathyroid adenoma (group B). None of the patients were affected by parathyroid carcinoma.

Results

Significant statistical differences were found in histological and immunohistochemical parameters as pseudocapsular invasion (p <  0.001), bands of fibrosis (p <  0.001), pronounced trabecular growth (p <  0.001), mitotic rates of > 1/10 high-power fields (HPFs) (p <  0.001), nuclear pleomorphism (p = 0.036), thick capsule (p <  0.001), Ki-67+ > 4% (p <  0.001), galectin-3 + (p = 0.002), and protein gene product (PGP) 9.5 + (p = 0.038).

Conclusions

Atypical parathyroid adenoma is a tumor that has characteristics both of typical adenoma and parathyroid carcinoma. The diagnosis is reached by excluding with strict methods the presence of malignancy criteria. Atypical parathyroid adenoma compared to typical adenoma showed significant clinical, hematochemical, histological, and immunohistochemical differences. We did not find any disease relapse in the 10 patients with atypical parathyroid adenoma during 60 months of follow-up time.

Publication and source details

Original title: Atypical parathyroid adenoma: clinical and anatomical pathologic features

Alessandro Galani; Riccardo Morandi; Mira Dimko; Sarah Molfino; Carla Baronchelli; Silvia Lai; Federico Gheza; Carlo Cappelli; Claudio Casella

World Journal of Surgical Oncology · 2021

© The Author(s) 2021https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-12T13:34:44.903858+00:00

DOI: 10.1186/s12957-021-02123-7 · PMC7818751